← back to the index
RX-014 Ergot dopamine agonist 2007

Permax (pergolide) — the Parkinson’s Drug Pulled in 2007 for Quintupling Heart-Valve Damage

cardiovascularfibroticvalvulopathycardiologymovement-disordersneurology1990s2000s
Patients exposed
Hundreds of thousands of Parkinson's patients over ~19 years
Documented harm
~5-fold (IRR 7.1) increase in valvular regurgitation; ~23% of users with moderate-to-severe valve damage
On market
1988→2007 (~19 years)
Status
Withdrawn

Summary

When the U.S. Food and Drug Administration announced on 29 March 2007 that the makers of pergolide had agreed to pull the drug from the American market, the action was filed as a routine post-market safety measure; the documented record shows that the fibrotic heart-valve mechanism that condemned Permax had been understood, in chemical detail, for years before the echocardiograms were read. Pergolide (marketed by Eli Lilly as Permax and approved by the FDA in 1988 as an adjunct to levodopa for Parkinson's disease) was an ergot-derived dopamine agonist that relieved tremor and rigidity by stimulating dopamine receptors — but it also bound potently to the 5-HT2B serotonin receptor on heart-valve tissue, the identical target that had driven the valvulopathy behind the 1997 fen-phen catastrophe.

The gap between promise and harm was not an unforeseeable side effect. Two studies published side by side in The New England Journal of Medicine on 4 January 2007 closed the case. René Schade and colleagues, mining the U.K. General Practice Research Database cohort of 11,417 patients, found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation. Renzo Zanettini's echocardiographic study found clinically important (moderate-to-severe) regurgitation in 23.4 percent of pergolide patients versus 5.6 percent of controls — and, decisively, 0 percent in patients on non-ergot dopamine agonists, which do not hit the 5-HT2B receptor.

The verdict is therefore plain at the outset: a drug with no proven efficacy advantage over safer, mechanistically distinct alternatives kept hundreds of thousands of Parkinson's patients exposed to a known fibrotic hazard years after the signal was legible. The FDA asked Lilly to add valvulopathy to the warnings section in 2003 and mandated a boxed warning in 2006; neither step removed the drug. Only the 2007 NEJM pair forced a withdrawal the pharmacology had argued for since at least 2002 — a quieter case than the blockbuster scandals, with no settlement fund and no Senate hearing, only a back-of-the-shelf agent kept in front-line use long after a receptor profile shared with a recalled diet drug had told clinicians exactly where to look.

Timeline

1988
FDA approves Permax
Pergolide mesylate (NDA 019385, Eli Lilly) is approved as an adjunctive treatment to levodopa/carbidopa for the signs and symptoms of Parkinson's disease.
1990s
Pergolide becomes a workhorse adjunct
As an ergot-derived dopamine agonist it is prescribed widely for advancing Parkinson's; hundreds of thousands of patients are treated over the drug's market life.
1997
The fen-phen precedent
Fenfluramine is withdrawn after causing valvular heart disease via 5-HT2B serotonin-receptor agonism — establishing the exact mechanistic template that ergot dopamine agonists would later be shown to share.
2002
First valvulopathy case reports
Published case series link pergolide to restrictive, fibrotic valve disease in Parkinson's patients, raising the serotonergic mechanism explicitly.
2003
Label warning, not withdrawal
The FDA asks Lilly to add cardiac valvulopathy to the warnings section of Permax labeling; the drug stays on the market and in active prescribing.
2004
Lilly divests; Valeant takes over Permax
Brand rights pass to Valeant Pharmaceuticals while generic pergolide (Par, Teva) continues to be dispensed.
2006
Boxed warning mandated
Accumulating fibrosis reports prompt the FDA to require a boxed ("black box") warning on pergolide labeling — the agency's strongest pre-withdrawal step.
2007-01-04
Two NEJM studies land
Schade et al. (N Engl J Med 2007;356:29-38) report a pergolide incidence-rate ratio of 7.1 for valve regurgitation; Zanettini et al. (356:39-46) find moderate-to-severe regurgitation in 23.4% of pergolide users versus 0% on non-ergot agonists.
2007-03-29
FDA announces voluntary withdrawal
In a Public Health Advisory, the NDA and ANDA holders (Valeant for Permax; Par and Teva for generics) agree to withdraw pergolide from the U.S. market over the risk of serious heart-valve damage.
2007
Transition guidance issued
The FDA and movement-disorder specialists advise that patients not stop abruptly but be switched to non-ergot dopamine agonists or other therapy, given the abrupt-withdrawal risks of dopaminergic agents.
2007-onward
Veterinary survival
Pergolide remains in use in horses for pituitary pars intermedia dysfunction (equine Cushing's), later marketed as Prascend by Boehringer Ingelheim — the molecule endures where the human market closed.

The Ergot Bargain: A Dopamine Agonist Built on a Serotonergic Scaffold

Pergolide was a child of ergot chemistry, the alkaloid family that gave medicine ergotamine and bromocriptine. Its therapeutic value was real: by stimulating D1 and D2 dopamine receptors it smoothed the motor fluctuations of patients whose levodopa was wearing off, and through the 1990s it became a standard adjunct. But the ergot scaffold that made pergolide a dopamine agonist also made it a potent agonist at the 5-HT2B serotonin receptor — densely expressed on cardiac-valve fibroblasts. Chronic 5-HT2B stimulation drives those cells to proliferate and lay down fibrous tissue, thickening and stiffening the valve leaflets until they no longer close cleanly; the result is regurgitation, blood leaking backward through the mitral, aortic, or tricuspid valve. This was not exotic pharmacology by the time Permax matured. It was the documented engine of carcinoid valve disease, of methysergide and ergotamine fibrosis, and — most publicly — of the fenfluramine valvulopathy that forced fen-phen off the market in 1997. The biology that made pergolide useful and the biology that made it dangerous were different systems welded to one molecule, and the dangerous half had a receptor address toxicologists already knew by heart.

The Signal Hiding in Plain Sight: 2002 to 2006

The warning did not arrive with the 2007 studies; it arrived in 2002, when the first case reports described pergolide patients with restrictive, fibrotic valve disease and named the serotonergic mechanism. The institutional response was incremental. In 2003 the FDA asked Lilly to add valvulopathy to the Permax warnings section — a label edit, not a market action. Prescribing continued; the brand passed to Valeant in 2004 and kept moving through pharmacies as branded and generic pergolide. In 2006, with fibrosis reports mounting, the FDA escalated to a boxed warning, its strongest labeling tool. Yet a boxed warning is a caution, not a removal, and a drug with no efficacy advantage over safer non-ergot agonists — ropinirole and pramipexole, which do not bind 5-HT2B — remained an option physicians could still write. For roughly four years the question was treated as a labeling problem rather than a benefit-risk verdict, even though the comparator that would settle it already sat on the same shelf. Every quarter of delay let patients accumulate cumulative dose — precisely what the fibrosis tracked.

The Reckoning: Two Papers, One Withdrawal

Permax was undone not by a regulator's investigation but by two independent research teams publishing in the same NEJM issue on 4 January 2007. Schade and colleagues at Charité in Berlin ran a nested case-control analysis inside an 11,417-patient cohort drawn from the U.K. General Practice Research Database and found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation, with risk concentrated at daily doses above 3 mg and durations of six months or more. Zanettini's Italian echocardiographic study supplied the anatomical confirmation: moderate-to-severe regurgitation in 23.4 percent of pergolide patients and 28.6 percent of cabergoline patients, against 5.6 percent in controls — and zero percent among patients on non-ergot agonists. The contrast was the verdict. The harm was not generic to dopamine agonism; it tracked the 5-HT2B receptor exactly. Within three months the FDA had its answer. On 29 March 2007 the agency announced that Valeant, Par, and Teva had agreed to withdraw pergolide from the U.S. market, citing studies showing that up to roughly 22 to 23 percent of users developed detectable valve abnormalities through pergolide's action at 5-HT2B receptors — the same mechanism, the advisory noted, as fenfluramine. The drug was retired; the mechanism it shared with a recalled diet pill became the headline.

Contributing Factors

01
Mechanistic foreknowledge that was not treated as evidence
The 5-HT2B valvulopathy pathway was documented in carcinoid disease, in methysergide, and — catastrophically — in fen-phen years before pergolide was pulled. A drug whose binding profile included potent 5-HT2B agonism should have inherited that prior probability of harm. Instead the receptor data sat as a mechanistic curiosity until outcome studies independently rediscovered what the pharmacology had already predicted. Known mechanism is evidence; ignoring it converts a foreseeable harm into a "surprise."
02
A safer same-class comparator that made the risk gratuitous
Non-ergot dopamine agonists (ropinirole, pramipexole) delivered comparable Parkinson's efficacy without binding 5-HT2B and without causing valve disease. The harm pergolide carried was therefore not a price of treatment but an avoidable surplus. When an equally effective, mechanistically clean alternative already exists, continued exposure to the dangerous agent is a benefit-risk failure with no efficacy justification to weigh against it.
03
Regulatory incrementalism: labeling as a substitute for removal
The FDA's response escalated through warnings (2003) to a boxed warning (2006) before reaching withdrawal (2007). Each step communicated risk without ending it. A label change shifts liability and informs the diligent prescriber, but it does not stop the cumulative dosing that drives a dose-dependent fibrosis. Treating a mechanistic, dose-dependent harm as a communications problem guarantees that exposure continues while the paperwork is updated.
04
Cumulative-dose harm in a chronic, lifelong indication
Parkinson's is a progressive disease treated for years; pergolide's valvulopathy was driven by cumulative exposure and higher daily doses. The mismatch between a chronic indication and a cumulative toxin meant that the longest-treated, most dependent patients bore the greatest risk. Harms that scale with total dose are especially dangerous in lifelong therapies, where the patient cannot simply finish a course and stop.
05
Corporate hand-offs that diffused safety ownership
Permax originated with Eli Lilly, passed to Valeant, and ran alongside generics from Par and Teva. As the signal matured, no single steward owned the franchise's full safety arc; the molecule's accountability was distributed across an originator that had moved on and licensees and generic makers with limited post-market surveillance incentives. Diffuse ownership of an aging drug weakens the very party best positioned to act on its accumulating harm.

Aftermath

The material consequences were modest by the standards of pharmaceutical scandal: no multibillion-dollar settlement fund, no congressional testimony, no journal expression of concern — pergolide was an older adjunct near the end of its commercial life, not a marketing-driven blockbuster, and the litigation that followed was limited. The durable ripple was scientific. The pergolide and cabergoline episode hardened 5-HT2B receptor screening into a standing expectation, so that regulators and developers now treat appreciable 5-HT2B agonism as a structural red flag for valvular and fibrotic risk in later serotonergic agents. Cabergoline, the ergot cousin implicated in the same studies, survived in human use only at the far lower doses used for hyperprolactinemia, under cardiac monitoring. Pergolide itself did not vanish: it endures in veterinary medicine as Prascend (Boehringer Ingelheim) for equine Cushing's disease. What remains is a textbook entry rather than a household name — the case invoked when a drug's known receptor pharmacology already names its eventual harm and the institution waits for the outcome study to say out loud what the binding assay had said all along. Pergolide became the byword for foreseeable valvulopathy: the harm hiding in the pharmacology, not the data.

Lessons

  1. Treat a known toxic mechanism as a prior, not a footnote: when a drug binds a receptor with a documented harm signature — 5-HT2B for fibrotic valve disease — assume the harm until a trial proves its absence, rather than waiting for bodies to confirm the chemistry.
  2. When a safer same-class alternative exists, the burden flips: if an equally effective drug lacks the dangerous mechanism, continued use of the dangerous one needs an affirmative justification, and "it still works" is not one.
  3. Read a boxed warning as a confession that removal is overdue, not as a resolution: a labeling escalation strong enough to warrant a black box is a signal that the benefit-risk balance may already have tipped — count the patients still being dosed while the warning does its quiet work.
  4. For lifelong, cumulative-dose therapies, weight long-term and dose-dependent harms above short-term tolerability, because the most loyal, longest-treated patients are precisely the ones a cumulative toxin will reach first.
  5. Assign one durable owner to an aging drug's safety, so that corporate hand-offs and generic entry do not orphan the surveillance just as the post-market signal matures.

References